Online inquiry

IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6763MR)

This product GTTS-WQ6763MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TACSTD2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002353.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4070
UniProt ID P09758
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6763MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10768MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA M-70
GTTS-WQ14000MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ9498MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA J2898A
GTTS-WQ11770MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MK-1308
GTTS-WQ9172MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMGN-529
GTTS-WQ3074MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ103MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 1121B
GTTS-WQ9439MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IPH-2201
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW